Loading
MOMA-313 is an experimental small molecule from MOMA Therapeutics, in phase 1 trials for homologous recombination deficient solid tumours, prostate cancer and pancreatic cancer and other cancers.
MOMA-313 is a small molecule (oral) from MOMA Therapeutics. A potent and selective oral inhibitor of the helicase domain of DNA polymerase theta (Polθ), which is involved in repairing DNA double-strand breaks; developed alone and with the PARP inhibitor olaparib. Its furthest stage is phase 1, for homologous recombination deficient solid tumours, prostate cancer, pancreatic cancer and breast cancer. ClinicalTrials.gov registers it in one study linked below. NCT06545942 recruiting (registry, checked 3 Nov 2026); first patient dosed August 2024. Whether it works in people has not been established unless a trial below reports it.
A potent and selective oral inhibitor of the helicase domain of DNA polymerase theta (Polθ), which is involved in repairing DNA double-strand breaks; developed alone and with the PARP inhibitor olaparib. Connects to POLQ.
1.MOMA-313 slips into a pocket on POLQ.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"MOMA-313" OR ABSTRACT:"MOMA-313") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MOMA-313, not a curated reading list.
Shares MOMA Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares MOMA Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Breast cancer (all types), Metastatic cancer (cancer that has spread), Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares POLQ, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares MOMA Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/